The true cost of chemotherapy

January 04, 2021

Chemotherapy for breast cancer costs the UK economy more than £248 million annually, including 'out-of-pocket' personal costs of more than £1,000 per patient - according to new research from the University of East Anglia.

A new study published today is the first to investigate the total non-healthcare cost of chemotherapy to the UK.

It includes the cost of lost productivity, work absence, and personal costs such as paying for transport and parking for treatment, the cost of wigs and new bras, and over the counter medications.

The UEA research team say that better targeting of treatment could help avoid placing unnecessary costs upon patients, their caregivers and wider society.

Prof Richard Fordham, from UEA's Norwich Medical School, said: "Breast cancer is the most common cancer in women and second most common cancer overall with two million cases per year worldwide.

"Most patients require surgery, additional radiotherapy, chemotherapy, hormone therapy or a combination of these to reduce the risk of the cancer coming back. Around a third of breast cancer patients receive chemotherapy, but there are grey areas around which patients do and don't need chemotherapy.

"As well as the cost of the treatment itself, there are many societal and personal costs associated with chemotherapy. These might include taking time off work, paying for hospital transport or parking, paying for over-the-counter medications or dietary supplements, the cost of wigs, headscarves and new bras, and the cost of informal care.

"But until now it has not been known what the total cost of all of this really is. We wanted to find out what the true total cost of chemotherapy is for patients, caregivers and wider society, for treating breast cancer in the UK."

The research team collected data from sources including UK cancer registries, clinical guidelines and published patient survey data. Patient and staff views were collected through semi-structured interviews.

Key findings:
In addition, costs for the emotional wellbeing of carers could be as much as £82 million. Emotional wellbeing reflects how much additional income would be required to offset a wellbeing loss.

Dr Stephanie Howard-Wilsher, also of UEA's Norwich Medical School, said: "We spoke to breast cancer patients who had undertaken chemotherapy to better understand the actual experiences and impacts of these costs. We also interviewed healthcare staff involved in breast cancer care for their views on chemotherapy and associated costs.

"The interviews with patients really show the impact that breast cancer has on lives. They talk about their worlds just falling apart, and chemotherapy side effects like hair loss, tiredness, constipation and diarrhea, loss of taste. And they also talk about the emotional impact for their families and those caring for them.

Researcher Anna Sweeting, from UEA's Norwich Medical School, said: "Interviews with healthcare professionals showed us how patients cope with chemotherapy differently. For some patients, their cognitive function is never quite the same afterwards, they suffer with 'chemo brain'. And it also gave us insight into the impact for families, including children's mental health.

"Our work shows how chemotherapy carries significant and far-reaching indirect costs for society, as well as for patients and their carers - beyond the costs associated with the treatment itself."

"The greatest burden accrued to society is in patient productivity losses. Patient out-of-pocket expenses and costs of informal care were smaller by comparison but nevertheless significant. Better targeting of chemotherapy treatment could help avoid placing unnecessary costs upon patients, their caregivers and wider society," added health economist and former UEA researcher Krishnali Parsekar.
'Societal costs of chemotherapy in the UK: an incidence-based cost-of-illness model for early breast cancer' is published in the journal BMJ Open on January 5, 2021.

University of East Anglia

Related Breast Cancer Articles from Brightsurf:

Oncotarget: IGF2 expression in breast cancer tumors and in breast cancer cells
The Oncotarget authors propose that methylation of DVDMR represents a novel epigenetic biomarker that determines the levels of IGF2 protein expression in breast cancer.

Breast cancer: AI predicts which pre-malignant breast lesions will progress to advanced cancer
New research at Case Western Reserve University in Cleveland, Ohio, could help better determine which patients diagnosed with the pre-malignant breast cancer commonly as stage 0 are likely to progress to invasive breast cancer and therefore might benefit from additional therapy over and above surgery alone.

Partial breast irradiation effective treatment option for low-risk breast cancer
Partial breast irradiation produces similar long-term survival rates and risk for recurrence compared with whole breast irradiation for many women with low-risk, early stage breast cancer, according to new clinical data from a national clinical trial involving researchers from The Ohio State University Comprehensive Cancer Center - Arthur G.

Breast screening linked to 60 per cent lower risk of breast cancer death in first 10 years
Women who take part in breast screening have a significantly greater benefit from treatments than those who are not screened, according to a study of more than 50,000 women.

More clues revealed in link between normal breast changes and invasive breast cancer
A research team, led by investigators from Georgetown Lombardi Comprehensive Cancer Center, details how a natural and dramatic process -- changes in mammary glands to accommodate breastfeeding -- uses a molecular process believed to contribute to survival of pre-malignant breast cells.

Breast tissue tumor suppressor PTEN: A potential Achilles heel for breast cancer cells
A highly collaborative team of researchers at the Medical University of South Carolina and Ohio State University report in Nature Communications that they have identified a novel pathway for connective tissue PTEN in breast cancer cell response to radiotherapy.

Computers equal radiologists in assessing breast density and associated breast cancer risk
Automated breast-density evaluation was just as accurate in predicting women's risk of breast cancer, found and not found by mammography, as subjective evaluation done by radiologists, in a study led by researchers at UC San Francisco and Mayo Clinic.

Blood test can effectively rule out breast cancer, regardless of breast density
A new study published in PLOS ONE demonstrates that Videssa® Breast, a multi-protein biomarker blood test for breast cancer, is unaffected by breast density and can reliably rule out breast cancer in women with both dense and non-dense breast tissue.

Study shows influence of surgeons on likelihood of removal of healthy breast after breast cancer dia
Attending surgeons can have a strong influence on whether a patient undergoes contralateral prophylactic mastectomy after a diagnosis of breast cancer, according to a study published by JAMA Surgery.

Young breast cancer patients undergoing breast conserving surgery see improved prognosis
A new analysis indicates that breast cancer prognoses have improved over time in young women treated with breast conserving surgery.

Read More: Breast Cancer News and Breast Cancer Current Events is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to